SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Techniclone (TCLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Maurice Winn who wrote (2394)8/6/1998 11:14:00 PM
From: Bob L  Read Replies (1) of 3702
 
Maurice, a small point: It may be an oversimplification to say "Rituxan will target maybe 99% of the cancer cells in strongly CD20 positive people, you get relapse as the last 1% replicate." CD20-positive cells may appear in 90 or 99% of lymphoma patients, but the antibodies in Rituxan and Bexxar do not necessarily bind well to all of those cells. It appears that the cell shape/type of the particular lymphoma is a major factor. Rituxan and Bexxar appear to bind better to follicular cells than other types. This may be a better explanation of the less than 100% response rate and eventual relapse, than assuming that there is often only 1% of remaining cancer cells.

Cell type variations may also be part of the explanation of why Oncolym doesn't produce 100% response rates, but I haven't seen written speculation on this point.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News